24 results
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
14 May 24
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
7:45am
and Gilead.
Research & Development (R&D) Expenses: R&D expenses were $10.4 million for the quarter ended March 31, 2024, compared to $16.1 million
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
1 Apr 24
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4:15pm
were $44.7 million as of December 31, 2023, compared to $120.4 million as of December 31, 2022.
Research & Development (R&D) Expenses: R&D expenses … were $11.7 million for the quarter ended December 31, 2023, compared to $15.0 million for the quarter ended December 31, 2022. R&D expenses were $52.1
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
9 Nov 23
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
4:13pm
and cash equivalents were $59.8 million as of September 30, 2023, compared to $120.4 million as of December 31, 2022.
Research & Development (R&D) Expenses … : R&D expenses were $11.1 million for the quarter ended September 30, 2023, compared to $13.0 million for the quarter ended September 30, 2022
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
14 Aug 23
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
7:40am
30, 2023, compared to $120.4 million as of December 31, 2022.
Research & Development (R&D) Expenses: R&D expenses were $13.2 million for the quarter
8-K
EX-99.1
bwzrgwomf78b 7t6w
25 May 23
Regulation FD Disclosure
5:05pm
8-K
EX-99.1
9dj4zqynkp178byg 1v9
9 May 23
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
o02ini bv04
9 Nov 22
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
7:45am
8-K
EX-99.2
kf4o4
9 Nov 22
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
7:45am
8-K
EX-99.1
mzt0iqy4lt0yo2a7
9 Aug 22
Results of Operations and Financial Condition
7:36am
8-K
lf5sbj
16 Jun 22
Departure of Directors or Certain Officers
7:45am
8-K
EX-10.1
2jjzr
16 Jun 22
Departure of Directors or Certain Officers
7:45am
8-K
EX-99.2
gxhtj2a v2kbjc51v60
12 May 22
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
7:36am
8-K
EX-99.1
koxglih5
12 May 22
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
7:36am
DEF 14A
1mtqglmzxfmng
26 Apr 22
Definitive proxy
4:05pm
8-K
EX-99.1
3ksrf3 g3yberu
1 Mar 22
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
8:00am
8-K
EX-99.1
qs26uhrxlrc
2 Dec 21
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
8:00am
424B4
z34a2rv4syannccl
22 Oct 21
Prospectus supplement with pricing info
4:02pm
S-1/A
t258zt
18 Oct 21
IPO registration (amended)
6:04am